Symrise AG began 2025 with steady growth, reporting a 4.2% organic increase in sales for the first quarter, reaching €1.3 billion (US$1.48 billion). The company reaffirmed its full-year guidance, aiming for 5% to 7% organic growth, an EBITDA margin around 21%, and business free cash flow near 14%.
The Taste, Nutrition & Health segment, which includes Symrise’s pet food activities, posted 5.9% organic growth with Q1 sales of €799 million. The Pet Food division saw moderate sales gains, as strong palatability product performance offset softer results in pet nutrition. Capacity expansions in key regions are expected to support future growth.
“We once again delivered profitable growth despite continued macroeconomic uncertainty,” said Dr. Jean-Yves Parisot, CEO of Symrise AG. “The group’s performance is underpinned by our diversified portfolio and unique global platform. We remain confident in our outlook for the current year and in our ability to deliver profitable above-market growth through 2028.”
Symrise AG began 2025 with steady growth, reporting a 4.2% organic increase in sales for the first quarter, reaching €1.3 billion (US$1.48 billion). The company reaffirmed its full-year guidance, aiming for 5% to 7% organic growth, an EBITDA margin around 21%, and business free cash flow near 14%.
The Taste, Nutrition & Health segment, which includes Symrise’s pet food activities, posted 5.9% organic growth with Q1 sales of €799 million. The Pet Food division saw moderate sales gains, as strong palatability product performance offset softer results in pet nutrition. Capacity expansions in key regions are expected to support future growth.
“We once again delivered profitable growth despite continued macroeconomic uncertainty,” said Dr. Jean-Yves Parisot, CEO of Symrise AG. “The group’s performance is underpinned by our diversified portfolio and unique global platform. We remain confident in our outlook for the current year and in our ability to deliver profitable above-market growth through 2028.”
Symrise noted strong demand in beverage applications and robust sales across the EAME and Asia/Pacific regions. In addition, the company continues to advance its “ONE Symrise” strategy, including a review of its chemicals production footprint and potential strategic options for its terpene ingredient operations.
The group maintained its long-term growth target of 5% to 7% compound annual growth through 2028 and an EBITDA margin of 21% to 23%.
Adapted from a press release.